 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
25 News |  |
- | cyclophosphamide / Generic mfg., levocabastine / Generic mfg.
Preclinical, Journal: Levocabastine ameliorates cyclophosphamide-induced cardiotoxicity in Swiss albino mice: Targeting TLR4/NF-?B/NLRP3 signaling pathway. (Pubmed Central) - Jan 27, 2024
The results showed the protective role of LEV in restoring CP-induced cardiotoxicity in terms of inflammation, apoptosis, oxidative stress, cardiac injury and histopathological damage. Thus, levocabastine can be used as an adjuvant to cyclophosphamide in cancer treatment but a thorough study with various animal cancer models is further needed to establish the fact.
- | levocabastine / Generic mfg.
Journal: The Efficacy of Budesonide, Levocabastine, and Their Combination in Treatment of Vasomotor Rhinitis. (Pubmed Central) - Dec 11, 2023
Budesonide or levocabastine hydrochloride alone improved the nasal symptoms of patients with vasomotor rhinitis and reduced the levels of ECP, HA, LTB4, and VIP in nasal secretions. However, their combination improved the symptoms of patients more significantly than each drug alone.
- | Entereg (alvimopan) / Merck (MSD), Viracept (nelfinavir) / ViiV Healthcare, Roche
FDA event, Journal: In-silico identification of novel DDI2 inhibitor in glioblastoma via repurposing FDA approved drugs using molecular docking and MD simulation study. (Pubmed Central) - May 4, 2023
MD simulation (100?ns) of these protein-ligand docked complexes reveals that the stability and compactness of Alvimopan are high in comparison with Nelfinavir. Our in-silico (Molecular docking and Molecular dynamics simulation) studies pointed out that Alvimopan may be repurposed as a DDI2 inhibitor and can be used as a potential anticancer agent for the treatment of brain tumors.Communicated by Ramaswamy H. Sarma.
- | levocabastine / Generic mfg.
Preclinical, Journal: A mouse model of allergic conjunctivitis permitting tear eosinophil quantification. (Pubmed Central) - Sep 23, 2022
in experimental and clinical settings. In particular, the developed method, which measures the number of eosinophils in tears collected with phenol red threads, may enable the quantitative, objective, and noninvasive evaluation of the severity of allergic conjunctivitis.
- | levocabastine / Generic mfg.
Journal: Neurotensin and xenin stimulates pancreatic exocrine secretion through the peripheral cholinergic nerves in conscious sheep. (Pubmed Central) - Jul 10, 2022
A single intravenous injection of NTR-2 agonist levocabastine at 0.1-3 nmol /kg did not alter pancreatic exocrine secretion. These results suggest that both NT and xenin-25 effectively stimulates pancreatic exocrine secretion through the peripheral cholinergic system in sheep and that NTR-2 is not involved in the regulation of pancreatic exocrine secretion, however, we did not precisely determine the role of NTR-1 in the actions of both the peptides on pancreatic exocrine secretion.
- | Arbidol (umifenovir) / Pharmstandard
Journal: Bioactive components of different nasal spray solutions may defeat SARS-Cov2: repurposing and in silico studies. (Pubmed Central) - Jul 9, 2022
Furthermore, MD simulations were performed (triplicate) for 100 ns to confirm the stability of 8, 13, and 16 with said protein targets and to compute MM-PBSA-based binding-free energy calculations. Thus, bioactive components 8, 13, and 16 open the door for researchers and scientist globally to investigate them against SARS-CoV2 through in vitro and in vivo analysis.
- | Nasonex (mometasone furoate nasal spray) / Merck (MSD)
Journal: The add-on effect of an intranasal antihistamine with an intranasal corticosteroid in Japanese cedar pollinosis. (Pubmed Central) - Jul 1, 2022
Thus, bioactive components 8, 13, and 16 open the door for researchers and scientist globally to investigate them against SARS-CoV2 through in vitro and in vivo analysis. The intranasal antihistamine provided better control of not only nasal symptoms, but also of ocular symptoms, and decreased the need for rescue medications when added to intranasal corticosteroid treatment in JCP patients.
- | adapalene / Generic mfg.
Journal: Discovery of adapalene and dihydrotachysterol as antiviral agents for the Omicron variant of SARS-CoV-2 through computational drug repurposing. (Pubmed Central) - May 6, 2022
Particularly, adapalene, dihydrotachysterol, levocabastine and bexarotene came into prominence due to their non-interference with the normal physiological processes. Therefore, this study suggests that these approved drugs can be considered as drug candidates for further in vitro and in vivo studies to develop new treatment options for the Omicron variant of SARS-CoV-2.
- || levocabastine / Generic mfg.
Clinical, Journal: Effects of xenin-25 on insulin and glucagon secretions in healthy conscious sheep. (Pubmed Central) - Apr 1, 2022
A prior intravenous injection of the neurotensin receptor subtype-1 (NTR-1) antagonist SR 48692 at 100 nmol/kg did not modify the glucose-induced change in plasma insulin caused by xenin-25 at 300 pmol/kg, and intravenous injection of the NTR-2 agonist levocabastine at 1000 pmol/kg did not augment the insulin response to the glucose injection...The mRNAs of the three NTR subtypes were highly expressed in the ovine pancreas in comparison with the expression in the abomasum. These results suggest that xenin-25 released from the upper gastrointestinal tract plays a role of an insulinotropic factor in sheep, possibly through NTRs in the pancreatic islets, but not via NTR-2.
- levocabastine / Generic mfg., paroxetine / Generic mfg.
3,4-disubstituted piperidines synthesis via enantioselective Tsuji-Trost coupling and cope rearrangement (In-Person Room (Virtual Room)) - Jan 28, 2022 - Abstract #ACSSp2022ACS_Sp_5620;
The Cope rearrangement products were derivatized by reduction and oxidative amidation demonstrating the importance of such substrates and presenting the type of products that can be access through this methodology. As such these products are of high value and will provide insights into stereoselective strategies related to the synthesis of 3,4-difunctionalized piperidines.
- | levocabastine / Generic mfg.
Journal: Changes in synaptic proteins of the complex PSD-95/NMDA receptor/nNOS and mitochondrial dysfunction after levocabastine treatment. (Pubmed Central) - Jan 27, 2022
Results suggested that levocabastine administration induces alterations in synaptic proteins of the protein complex PSD-95/NMDA receptor/nNOS and in neuron cytoskeleton. Mitochondrial bioenergetics impairment may play a role in the functional link between synaptic proteins and NO synthesis.
- | levocabastine / Generic mfg.
Journal: Optimization of a histamine-induced allergic conjunctivitis model in Guinea pigs. (Pubmed Central) - Jan 5, 2022
For observations of symptoms of conjunctivitis, we eliminated ambiguity of evaluation by adopting the Draize scale and ensured a higher objectivity on the evaluation method. The drug efficacy evaluation of levocabastine hydrochloride in the prepared model revealed that drug efficacy of the antihistamine drug was captured according to the standardized test method and highly-reproducible results were obtained.
- | levocabastine / Generic mfg.
Journal: Biophysical insight into the interaction of levocabastine with human serum albumin: spectroscopy and molecular docking approach. (Pubmed Central) - Jun 30, 2021
Moreover, docking results indicate levocabastine binds to pocket near to the drug site-I in HSA via hydrogen bonding and hydrophobic interactions. Understanding the interaction of levocabastine with HSA is significant for the advancement of therapeutic and diagnostic strategies for optimal treatment results.Communicated by Ramaswamy H. Sarma.
- | levocabastine / Generic mfg.
New trial: Study of Medication for Nonallergic Rhinitis (NAR) Based on Cluster Analysis (clinicaltrials.gov) - Jun 28, 2019
P=N/A, N=80, Recruiting, Sponsor: Beijing Tongren Hospital
- ||||||| levocabastine / Generic mfg.
Trial completion: Clinical Trial to Evaluate the Efficacy and Safety of CKD-342 (clinicaltrials.gov) - Dec 27, 2016
P3, N=459, Completed, Sponsor: Chong Kun Dang Pharmaceutical
Understanding the interaction of levocabastine with HSA is significant for the advancement of therapeutic and diagnostic strategies for optimal treatment results.Communicated by Ramaswamy H. Sarma. Recruiting --> Completed
- || levocabastine / Generic mfg.
New P3 trial: Clinical Trial to Evaluate the Efficacy and Safety of CKD-342 (clinicaltrials.gov) - Jul 15, 2015
P3, N=459, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- Veramyst (fluticasone furoate nasal spray) / GSK
Enrollment change: A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine (clinicaltrials.gov) - Mar 12, 2014
P1, N=30, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed N=40 --> 30
- | Veramyst (fluticasone furoate nasal spray) / GSK
Trial completion: A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine (clinicaltrials.gov) - Mar 12, 2014
P1, N=30, Completed, Sponsor: GlaxoSmithKline
N=40 --> 30 Active, not recruiting --> Completed
- |||| Veramyst (fluticasone furoate nasal spray) / GSK
Trial completion: A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR) (clinicaltrials.gov) - Feb 26, 2014
P2, N=71, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| levocabastine / Generic mfg.
Trial completion: A Study to Assess Intranasal Repeat Dose Effect of Levocabastine in the Subjects With Allergic Rhinitis (clinicaltrials.gov) - Feb 12, 2014
P2, N=78, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Veramyst (fluticasone furoate nasal spray) / GSK
New P1 trial: A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine (clinicaltrials.gov) - Oct 10, 2013
P1, N=30, Completed, Sponsor: GlaxoSmithKline
- ||||| Veramyst (fluticasone furoate nasal spray) / GSK
New P2 trial: A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR) (clinicaltrials.gov) - Oct 6, 2013
P2, N=71, Completed, Sponsor: GlaxoSmithKline
- ||||| levocabastine / Generic mfg.
New P2 trial: A Study to Assess Intranasal Repeat Dose Effect of Levocabastine in the Subjects With Allergic Rhinitis (clinicaltrials.gov) - Sep 22, 2013
P2, N=78, Completed, Sponsor: GlaxoSmithKline